CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

NCT04271410 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia
Lymphoma, Large B-Cell, Diffuse
Leukemia, B-cell
Lymphoma, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

BIOLOGICAL: CD19 CAR-T cells

Sponsor

Chongqing Precision Biotech Co., Ltd